These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20375795)

  • 21. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
    Tang L; Zheng M; Xiong Y; Ding H; Liu FY
    Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
    Guardiola E; Delroeux D; Heyd B; Combe M; Lorgis V; Demarchi M; Stein U; Royer B; Chauffert B; Pivot X
    World J Surg Oncol; 2009 Feb; 7():14. PubMed ID: 19203351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of interval debulking in advanced ovarian cancer patients.
    Suprasert P; Tiyanon J; Kietpeerakool C
    Asian Pac J Cancer Prev; 2008; 9(3):519-24. PubMed ID: 18990031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
    Anfinan N; Sait K; Ghatage P; Nation J; Chu P
    Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
    Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
    Kang S; Jong YH; Hwang JH; Lim MC; Seo SS; Yoo CW; Park SY
    Ann Surg Oncol; 2011 Dec; 18(13):3824-7. PubMed ID: 21691879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration.
    Kato K; Nishikimi K; Tate S; Kiyokawa T; Shozu M
    World J Surg Oncol; 2015 Jul; 13():230. PubMed ID: 26228239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402).
    Hirakawa T; Minaguchi T; Itani Y; Kasamatsu Y; Murase S; Sakurada S; Nagano H; Takehara K; Tsuruta T; Arakawa A; Kawano K; Tsubamoto H; Ushiwaka T; Mori T; Iwai K; Saito M; Morisawa H; Saito F; Yoshida K; Kaneuchi M; Sato H; Ito K; Nasu K
    World J Surg Oncol; 2017 Jul; 15(1):132. PubMed ID: 28716033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
    Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.
    Lackman F; Carey MS; Kirk ME; McLachlin CM; Elit L
    Gynecol Oncol; 2003 Aug; 90(2):407-12. PubMed ID: 12893209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.